Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Current Liabilities (2016 - 2026)

Akebia Therapeutics has reported Total Current Liabilities over the past 11 years, most recently at $162.9 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 101.37% to $162.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.9 million through Dec 2025, up 101.37% year-over-year, with the annual reading at $162.9 million for FY2025, 101.37% up from the prior year.
  • Total Current Liabilities was $162.9 million for Q4 2025 at Akebia Therapeutics, up from $133.4 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $261.1 million in Q4 2021 and troughed at $65.7 million in Q3 2024.
  • The 5-year median for Total Current Liabilities is $124.1 million (2022), against an average of $139.7 million.
  • Year-over-year, Total Current Liabilities plummeted 66.09% in 2023 and then soared 102.98% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $261.1 million in 2021, then plummeted by 50.38% to $129.5 million in 2022, then fell by 22.9% to $99.9 million in 2023, then fell by 18.98% to $80.9 million in 2024, then skyrocketed by 101.37% to $162.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Total Current Liabilities are $162.9 million (Q4 2025), $133.4 million (Q3 2025), and $118.7 million (Q2 2025).